source
- Argenx to acquire Forte Biosciences for $2.2 billion, securing phase-2 vitiligo antibody FB102Argenx announced it will buy Forte Biosciences for $2.2 billion, gaining access to FB102, an anti‑CD122 antibody currently in phase‑2 trials for vitiligo and celiac disease. In a recent phase 1b s…
- Virginia judge orders FDA to revisit Biden-era mifepristone restrictionsA federal judge in Virginia has ruled that the FDA must reexamine certain restrictions on the abortion medication mifepristone that were put in place during the previous administration. The judge…